Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05423197
89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
Overview
The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Sponsor
Stanford University
Phase
Phase 2
Contacts
Grace Yi (CONTACT)
gracesyi@stanford.edu
650-723-1423
Roan C Raymundo, BS (CONTACT)
rcraymun@stanford.edu
(650) 721-4071
Fred Baik, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT05423197Drug / Compound
panitumumab
Isotope(s):
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Target(s):
- EGFR
Ligand Class: Antibodies
Chelator: DFO
Eligibility
Inclusion
- Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed.
- Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
Exclusion
Exclusion criteria not yet provided.
Share your feedback
Help us improve your experience